Garcinia Biflavonoid 1 Improves Lipid Metabolism in HepG2 Cells via Regulating PPARα

Garcinia biflavonoid 1 (GB1) is one of the active chemical components of and is reported to be capable of reducing the intracellular lipid deposition, which is the most significant characteristic of non-alcoholic fatty liver disease. However, its bioactive mechanism remains elusive. In the current s...

Full description

Saved in:
Bibliographic Details
Published in:Molecules (Basel, Switzerland) Switzerland), 2022-03, Vol.27 (6), p.1978
Main Authors: Chen, Hai-Xin, Yang, Fan, He, Xin-Qian, Li, Ting, Sun, Yong-Zhi, Song, Jian-Ping, Huang, Xin-An, Guo, Wen-Feng
Format: Article
Language:English
Subjects:
Apoptosis
Biflavonoids - pharmacology
Biological activity
Deposition
fatty acid oxidation
Fatty acids
Fatty liver
Garcinia
garcinia biflavonoid 1
Hep G2 Cells
Humans
Inflammation
Interleukin 1
Interleukin 10
Lipid Metabolism
Lipids
Liver
Liver diseases
Metabolism
Oleic acid
Oxidative metabolism
Oxidative stress
Palmitic acid
PPAR alpha - genetics
PPARα
Triglycerides
Tumor necrosis factor-α
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Garcinia biflavonoid 1 (GB1) is one of the active chemical components of and is reported to be capable of reducing the intracellular lipid deposition, which is the most significant characteristic of non-alcoholic fatty liver disease. However, its bioactive mechanism remains elusive. In the current study, the lipid deposition was induced in HepG2 cells by exposure to oleic acid and palmitic acid (OA&PA), then the effect of GB1 on lipid metabolism and oxidative stress and the role of regulating PPARα in these cells was investigated. We found that GB1 could ameliorate the lipid deposition by reducing triglycerides (TGs) and upregulate the expression of PPARα and SIRT6, suppressing the cell apoptosis by reducing the oxidative stress and the inflammatory factors of ROS, IL10, and TNFα. The mechanism study showed that GB1 had bioactivity in a PPARα-dependent manner based on its failing to improve the lipid deposition and oxidative stress in PPARα-deficient cells. The result revealed that GB1 had significant bioactivity on improving the lipid metabolism, and its potential primary action mechanism suggested that GB1 could be a potential candidate for management of non-alcoholic fatty liver disease.
ISSN:1420-3049
1420-3049
DOI:10.3390/molecules27061978